focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
SNG now over 500%, congrats anyone holding those! All my dough is here so hoping for a similar result soon. IFN b1 a now certainly on the radar. Very happy to be holding here especially with sax previous post on Potential at FARN!
Thanks oilman and co for all your research and hard work, it’s very much appreciated by me and fellow PI’s I’m sure.
All looking good and hopefully some confirmation news that we’re still very much in the game will land soon to steady the ship and begin the ascent to where we were a few weeks ago.
Good luck all
Are those pesky MM’s aware of good news on the way and dropping the price to spook small investors and pick up a load of shares on the cheap to sell them at huge premiums? I’ve seen it happen before!
I’ve also seen a SP rise significantly to encourage buying the day before a negative RNS so never think they don’t know what’s coming.
Here’s hoping for some good news.
All the best
The scientific community is currently focused on discovering new therapeutics to treat COVID-19 and we are very pleased to be supporting these efforts, now with three trials investigating the potential of Traumakine in severely ill patients. We continue to believe in the potential of Traumakine as a future treatment for ARDS and one that could have significant impact on the intensive-care burden from COVID-19. We look forward to providing updates on both development programmes as they progress."
The World Health Organization (WHO) has approved bexmarilimab as the International Nonproprietary Name (INN) for Clevegen.
· An additional cohort has been added to Part II of the ongoing MATINS trial, exploring the potential of bexmarilimab in patients with anaplastic thyroid cancer, currently without effective treatment. This follows announcement by the Company on 30 March 2020 of the cancer types to be included in Part II of the trial.
· Clinical expansion plans for bexmarilimab will include the investigation of alternative dosing cycles, as pharmacodynamics markers may indicate a need for shorter frequencies, as well as further studies in additional clinical settings.
· Clinical studies are being planned to investigate bexmarilimab in combination with standard of care (SOC) as a first-line therapy in selected advanced solid tumours, and as a standalone neoadjuvant therapy for patients with early stage colon cancer. The Company currently expects patient recruitment for a small number of cohorts to complete around late Q3 with discussions with the FDA to follow in Q4.
Apologies if this has been posted before but worth a read.
https://www.chemistryworld.com/podcasts/interferon-beta/4011639.article
Markku was quoted saying the day the phase III results came in as “the worst day of his life”, that’s a pretty strong statement, he definitely won’t be compromising T in the new phase III or WHO and REMAP trials. He knows damn well what he has and without corticosteroids combination it will work.
Itsall I’ve had my trousers pulled down many times on AIM, but that’s not happening here!
CEO mentioned in last interview that shareholders will see significant value added to the share price in the next 8-12 months.
We are in a very good place with global recognition with remap-cap and WHO trials. Very exciting stuff and AIM free float shrinking daily.
Swedish pension fund heavily invested, they don’t just invest that kind of dough on a whim.
Very happy to be invested here, complete no brainier.
https://youtu.be/4jqShDK15vI
Mani - listen to the pro active investor interview 1m 50 secs in.